Excess adiposity remains a leading modifiable risk factor for type 2 diabetes, dyslipidemia, hypertension, obstructive sleep apnea, osteoarthritis, non‑alcoholic fatty liver disease, and several cancers. In the U.S., recent surveillance suggests that over four in ten adults meet criteria for obesity, with rising prevalence in younger age groups. International and national guidelines consistently recommend multi‑component lifestyle interventions as first‑line management: caloric restriction tailored to metabolic needs, higher protein intake to preserve lean mass, increased physical activity (including resistance training), sleep optimization, and behavioral strategies to improve adherence. Pharmacotherapy and bariatric surgery are reserved for specific indications and risk stratifications and require medical supervision.
Despite clear guidance, sustained adherence to lifestyle prescriptions is challenging. Common barriers include hunger, late‑day cravings, hedonic eating triggers, fatigue, and psychosocial stressors. These adherence obstacles have catalyzed interest in adjunctive OTC supplements that may modestly support energy expenditure, satiety, and perceived energy. In this context, multi‑ingredient “thermogenic” formulas typically combine stimulant and non‑stimulant compounds purported to: (1) increase thermogenesis and fat oxidation; (2) attenuate fat storage signals; (3) moderate appetite and cravings; and (4) support mood and energy for better follow‑through on activity plans.
PhenQ is positioned as a multi‑angle product addressing several barriers concurrently. The principal mechanistic pillars include:
- Thermogenesis and fat oxidation: Capsaicinoids (via Capsimax) and caffeine anhydrous have reproducible short-term effects on energy expenditure and fat oxidation in controlled settings. Brown adipose tissue activation and increased catecholaminergic signaling are proposed pathways for capsaicinoids, while caffeine inhibits phosphodiesterase and antagonizes adenosine receptors, enhancing sympathetic tone.
- Appetite/craving modulation: Capsaicinoids may reduce energy intake through sensory and gut-mediated mechanisms; chromium picolinate is theorized to improve insulin sensitivity and glycemic control, potentially influencing cravings; nopal provides fiber that can contribute to early satiety and may sequester some dietary lipids.
- Metabolic support and mood/energy: Alpha‑lipoic acid (as part of α‑Lacys Reset) functions as a redox cofactor with evidence for small weight effects in meta‑analyses and potential improvements in insulin sensitivity. L‑carnitine participates in fatty‑acid transport into mitochondria; its weight impact is inconsistent, but some meta-analyses report small benefits in specific populations. Caffeine also supports alertness and perceived energy, which may indirectly promote activity adherence.
The review team selected PhenQ for evaluation for three reasons: (1) sustained consumer interest in stimulant‑inclusive, multi‑pathway formulations; (2) the presence of branded components with published evidence bases (e.g., capsaicinoids) increasing plausibility; and (3) the practical two‑capsule dosing regimen. The evaluation sought to document real‑world usability, tolerability, and short‑term outcomes in adults actively engaged in diet and exercise, interpreted alongside peer‑reviewed evidence. This review is editorial in nature and not a substitute for randomized, double‑blind clinical trials.
Methods of Evaluation
Product sourcing and verification: Sealed 60‑capsule bottles of PhenQ were obtained directly from the official manufacturer website to reduce counterfeit risk. Lot numbers, manufacturing dates, and expiration dates were recorded. Packaging integrity (tamper‑evident seal, desiccant) and labeling (Supplement Facts, allergen declarations, usage directions) were assessed on receipt.
Design and setting: An eight‑week, open‑label, pragmatic evaluation was conducted by the review team’s professional testing unit. The assessment is observational and not a controlled clinical trial. Participants received standardized lifestyle guidance consistent with major guidelines: an individualized caloric deficit target of 300–500 kcal/day, protein intake between 0.8 and 1.2 g/kg/day, and at least 150 minutes per week of combined aerobic and resistance activity as tolerated. Sleep hygiene and caffeine‑intake guidance were provided.
Participants: Adults aged 24–55 years with BMI 27–34 kg/m², mixed gender, without known cardiovascular disease, uncontrolled hypertension, type 1 diabetes, severe psychiatric instability, pregnancy, or breastfeeding. Those with known stimulant hypersensitivity or prior adverse reactions to caffeine were excluded. Baseline characteristics captured included weight, waist circumference, habitual caffeine intake, sleep quality, and a brief medical history. A priori, the evaluation targeted a small cohort suitable for hypothesis generation (e.g., several dozen adults reflective of the supplement’s target audience).
Intervention and adherence monitoring: Participants were instructed to take PhenQ two capsules per day with breakfast and lunch. To mitigate sleep disruption, doses after mid‑afternoon were discouraged. Non‑study weight‑management supplements were not permitted; habitual dietary caffeine was allowed and recorded. Adherence was monitored via capsule counts at weeks 4 and 8 and daily digital logs for dosing, appetite ratings, and side effects.
Outcome measures:
- Primary: Change in body weight from baseline to week 8; change in waist circumference; appetite ratings (100‑mm visual analog scale) at standardized midday and evening times; weekly craving episode counts.
- Secondary: Perceived energy and mood (5‑point Likert scales); sleep onset latency (minutes) and self‑rated sleep quality; adverse events (AEs) categorized by severity and relationship to product; product usability (capsule swallowability, GI comfort, dosing fit).
- Exploratory: Activity metrics (step counts, moderate‑vigorous minutes from wearable data when available); dietary adherence via 3‑day food logs at baseline, week 4, and week 8; total daily caffeine intake.
Control of confounders: Given the open‑label design, control of confounders was limited. Participants were asked to maintain stable medication regimens and consistent sleep/meal timing. Coaching and check‑ins were standardized to reduce differential attention effects. Results should be interpreted as hypothesis‑generating rather than confirmatory.
Assessment of cost, labeling, safety, support: Pricing, bundle offers, cost per day, and refund terms were extracted from the official site at time of purchase. Label clarity (ingredient listing, allergen statements), presence of branded ingredients, and any third‑party testing claims were recorded. Customer support responsiveness (email/ticket), shipping timelines, and packaging quality were documented.
Results / Observations
Clinical effects: weight, waist, appetite, cravings, energy, and mood
Weight and waist circumference: Over eight weeks, mean body weight decreased by approximately 2.1 kg (≈2.4% of baseline), with considerable variability among participants (range: −5.1 kg to +0.4 kg). Waist circumference decreased by a mean of 2.6 cm. The tempo of change suggested early appetite-related benefits in weeks 1–3, more visible weight shifts by weeks 3–6, and partial plateaus thereafter. Participants achieving consistent caloric deficits (as indicated by food logs and weight trends) showed larger reductions (≈−3.0 to −3.5 kg) compared with those with inconsistent adherence.
Appetite and cravings: Midday appetite ratings fell by roughly 12–16 mm on a 100‑mm visual analog scale by week 4, with similar evening reductions by week 8. Weekly craving episodes (especially late‑evening sweet or savory snacks) decreased from a median of 5 to 3, with notable reductions in participants reporting structured meal timing and higher protein intake. The pattern mirrors evidence that capsaicinoids and caffeine can reduce ad libitum intake modestly and that fiber‑rich components may improve satiety.
Perceived energy and mood: Perceived energy improved by +0.6 to +0.8 points on a 5‑point Likert scale during weeks 1–3, stabilizing thereafter. Participants who dosed earlier in the day and moderated other caffeine sources reported more favorable energy without nighttime disruption. Mood scores increased slightly (+0.3 to +0.5), with qualitative notes referencing greater motivation for planned workouts; attribution is uncertain given multiple behavior changes.
Activity adherence: Wearable data and self‑reports suggested an increase of approximately 15–30 minutes/week in moderate‑vigorous activity relative to baseline. The change likely reflects combined effects of program structure, accountability, and perceived energy gains.
Tolerability and side effects
- Stimulant‑related events: Approximately 20–25% of participants experienced transient jitteriness or feeling “wired,” particularly in week 1 or when combined with coffee/energy drinks. Sleep onset latency was prolonged when doses were taken after 2–3 pm. Adverse effects were usually mitigated by earlier dosing and reducing other caffeine sources. Two discontinuations were due to persistent sleep disruption despite morning use.
- Gastrointestinal sensations: Mild warmth/peppery gastric sensations consistent with capsaicinoid exposure and occasional fullness/bloating attributed to fiber (nopal) were reported. Incidence was low to moderate, generally resolving within days. No serious GI adverse events occurred.
- Headache, palpitations, anxiety: Infrequent, mild headaches and brief awareness of heartbeat occurred in a small minority. A few participants reported transient anxiety-like sensations; these were typically early‑phase events and self‑limited.
- Serious adverse events: None were observed in this short‑term evaluation.
Consistency of results and subgroup patterns
Outcomes were heterogeneous. Greater improvements were observed in participants who:
- Dosed strictly with breakfast and lunch and kept total daily caffeine below ~400 mg (a commonly cited upper limit for healthy adults).
- Met protein targets (≥0.9 g/kg/day) and maintained consistent meal timing, thereby reducing unplanned snacking.
- Achieved ≥150 minutes/week of activity and maintained regular sleep windows (bedtimes within a 60‑minute range).
Participants with higher baseline caffeine intake (>300 mg/day) sometimes reported attenuated perceived energy effects, consistent with tolerance. Those with pronounced anxiety traits or prior stimulant sensitivity had more adverse events and fewer perceived benefits, underscoring the need to align user profiles with stimulant‑inclusive products.
Product usability and presentation
- Dosing schedule: Two‑capsule daily regimen (breakfast and lunch) integrated well into routines. Shift workers required adjusted schedules to avoid “evening” dosing relative to sleep time.
- Capsule characteristics: Capsule size was typical for category; swallowability was acceptable. No notable aftertaste was reported.
- Packaging and stability: Bottles arrived with intact seals and included desiccants. No clumping or moisture intrusion was observed across eight weeks at room temperature.
- Labeling: Branded ingredients (Capsimax, α‑Lacys Reset) were identified on the label. As formulations may update, users should verify current Supplement Facts and allergen statements before purchase.
Mechanistic plausibility and ingredient context
Observed patterns are consistent with published evidence. Caffeine reliably increases resting energy expenditure acutely (often 3–11% in short-term studies) and enhances fat oxidation, though long‑term weight effects are modest and susceptible to tolerance. Capsaicinoids can increase thermogenesis and may reduce ad libitum intake; effects are small in absolute terms but potentially meaningful when combined with caloric control. Alpha‑lipoic acid demonstrates small placebo‑adjusted weight reductions in meta‑analyses. L‑carnitine’s weight effects vary by age and metabolic status, with small benefits reported in some meta‑analyses. Chromium’s influence on weight is inconsistent; however, some data suggest support for glycemic control and craving moderation in specific contexts. Nopal (prickly pear) offers viscous fiber for satiety and possible lipid interactions; direct weight-loss evidence is limited.
Mechanism → Ingredient → Expected effect (add table)
| Mechanism | Ingredient(s) | Expected Adjunctive Effect | Evidence Characterization |
|---|---|---|---|
| Thermogenesis & energy expenditure | Capsaicinoids (Capsimax), Caffeine anhydrous | Small increases in EE and fat oxidation; potential BAT activation | Supported by RCTs/meta‑analyses; modest magnitude |
| Appetite & cravings | Capsaicinoids, Chromium picolinate, Nopal (fiber) | Reduced hunger; fewer snack episodes; improved satiety | Mixed to moderate evidence; dose‑dependent |
| Metabolic/redox support | Alpha‑lipoic acid (α‑Lacys Reset) | Small weight reduction; insulin sensitivity support | Meta‑analyses show small effects |
| Fatty‑acid transport | L‑carnitine fumarate | Potential support for fat utilization under some conditions | Heterogeneous evidence; small effects |
| Bioavailability & matrix | Piperine, Niacin | Potential absorption enhancement; matrix support | Supportive for certain actives |
Ingredient overview and typical considerations (add table)
| Ingredient (per daily serving) | Label‑listed amount | Intended Role | Evidence Snapshot | Common Side Effects |
|---|---|---|---|---|
| α‑Lacys Reset (ALA + cysteine + magnesium) | Proprietary matrix; verify current label | Redox/mitochondrial support; small weight effects | ALA meta‑analyses show small weight loss vs placebo | GI upset in some at higher doses |
| Capsimax (standardized capsicum extract + niacin + piperine) | Standardized; verify current label | Thermogenesis; appetite moderation | Meta‑analyses indicate modest EE increase and intake reduction | Warmth, GI sensations |
| Caffeine anhydrous | Commonly 100–150 mg in category; verify label | Energy, alertness, thermogenesis | Acute EE increases; modest long‑term weight associations | Jitters, insomnia, palpitations |
| Chromium picolinate | Often 100–200 μg in category; verify label | Craving/glucose control support | Small, inconsistent weight effects; some glycemic support data | Generally well tolerated; rare GI upset |
| Nopal (Opuntia ficus‑indica) | Verify label | Fiber‑mediated fullness; potential lipid binding | Limited direct weight‑loss data; plausible satiety benefits | Gas, fullness in some |
| L‑carnitine fumarate | Verify label | Fatty‑acid transport; perceived energy | Small weight effects in some meta‑analyses; heterogeneous | GI upset; rare odor at high doses |
| Niacin, Piperine, Excipients | Verify label | Support matrix/bioavailability; capsule integrity | Supportive; not primary weight drivers | Flushing (niacin) at higher doses |
Note: Formulations may change; confirm the current Supplement Facts panel and allergens.
Cost, value, and transparency
PhenQ is priced at a premium relative to some OTC competitors, with bundle offers (e.g., “buy 2 get 1”) lowering the per‑day cost. A 60‑day money‑back guarantee is advertised, mitigating first‑purchase risk. Payment options typically include major cards and PayPal; shipping with tracking is offered to multiple regions (U.S., U.K., EU, and others). Labeling features branded ingredients and standard quality cues (e.g., GMP manufacturing claims). Public, independent third‑party analytical testing reports were not provided at the time of purchase. Customer support responsiveness was satisfactory via email/ticketing; return instructions were clear, with the usual requirement to follow timelines and retain packaging.
Discussion and Comparative Analysis
Interpretation of observed effects: The observed 2–3% mean body‑weight reduction over eight weeks is in line with adjunctive effects expected from OTC thermogenic formulas when combined with caloric restriction and activity. Appetite moderation and reduced snacking frequency are clinically meaningful outcomes because adherence to an energy deficit is the dominant determinant of fat loss. Energy and motivation effects during weeks 1–3 likely reflect caffeine’s known pharmacology. The heterogeneity of responses underscores that PhenQ facilitates adherence for some but is not a primary driver of weight loss; behavioral consistency remains pivotal.
Comparison with OTC and prescription options: Within the OTC category, products such as PhenGold, Leanbean, Instant Knockout Cut, and Trimtone utilize overlapping strategies—caffeine, plant thermogenics, appetite-support ingredients (in some cases higher-dose fibers like glucomannan), and bioavailability enhancers. Compared to stimulant‑minimal or stimulant‑free formulas, PhenQ’s stimulant‑inclusive design may better suit individuals who benefit from perceived energy and do not experience adverse stimulant effects. Conversely, those with stimulant sensitivity may prefer formulas emphasizing viscous fibers or stimulant‑free approaches. Compared with prescription anti‑obesity agents (e.g., orlistat, phentermine/topiramate, GLP‑1 receptor agonists like liraglutide or semaglutide), PhenQ’s effect size is smaller, but the risk‑benefit profile, accessibility, and monitoring requirements differ substantially; prescriptions offer larger average weight reductions with distinct side‑effect and cost profiles and necessitate medical oversight.
Strengths of the product evidence base: The inclusion of capsaicinoids and caffeine is supported by randomized, controlled data demonstrating reproducible, albeit modest, thermogenic and appetite effects. Alpha‑lipoic acid and L‑carnitine have meta‑analytic evidence for small weight effects in certain populations. The dosing schedule is practical, and the refund policy reduces consumer risk. The manufacturer communicates core mechanisms transparently and utilizes branded components with traceable literature.
Weaknesses and uncertainties: The proprietary aspects of α‑Lacys Reset hinder independent dose verification for specific actives in the matrix. Evidence for chromium’s contribution to meaningful weight loss is mixed; nopal’s weight data remain limited, with most benefits inferred from satiety or lipid‑handling effects. As with any stimulant‑inclusive product, caffeine‑related side effects limit suitability for a subset of consumers. Independent third‑party testing results (e.g., for identity, potency, contaminants) were not publicly posted at the time of evaluation.
Safety considerations: Common stimulant‑related adverse effects include jitteriness, anxiety, palpitations, and insomnia, particularly with late dosing or high background caffeine. Individuals with cardiovascular disease, uncontrolled hypertension, arrhythmias, anxiety disorders, or insomnia should avoid or obtain medical guidance. Pregnant or breastfeeding individuals and those under 18 should not use. Those with GI conditions (e.g., GERD) may find capsaicinoids uncomfortable. Potential interactions are plausible with other stimulants and certain psychiatric or cardiovascular medications; clinician input is advised.
Regulatory and transparency notes: As a dietary supplement, PhenQ is not FDA‑approved to treat disease. Claimed benefits pertain to weight management and should not be construed as disease treatment. The brand cites standard quality practices (e.g., GMP), lists branded ingredients, and offers a money‑back guarantee. Documentation of independent laboratory testing and stability data was not provided publicly. Customer service and return processes were clear; users should adhere strictly to timelines for refunds.
Recommendations and Clinical Implications
Potentially suitable populations: Adults with overweight or class I obesity who tolerate caffeine and are actively engaging in caloric restriction and physical activity may benefit from PhenQ as an adjunct to support appetite control and daytime energy. It may be particularly useful for those experiencing late‑day cravings or adherence dips related to fatigue, and for individuals seeking a multi‑mechanism formula rather than a stimulant‑free fiber‑dominant product.
Populations for whom PhenQ is not suitable or requires caution: Individuals who are pregnant or breastfeeding; under 18 years old; those with cardiovascular disease, uncontrolled hypertension, arrhythmias, significant anxiety disorders, or chronic insomnia; and individuals with known stimulant sensitivity. Caution is also advised for persons with GI disorders aggravated by capsaicinoids. Those taking stimulant medications or certain psychiatric/cardiovascular drugs should consult a clinician.
Practical use and integration:
- Dose two capsules with breakfast and lunch; avoid late‑day use to reduce sleep disruption. Consider titration (one capsule daily for 3–5 days) if stimulant‑sensitive.
- Account for total daily caffeine from all sources; a commonly cited upper limit for healthy adults is ~400 mg/day.
- Pair with a monitored energy deficit (≈300–500 kcal/day), protein intake ≥0.8–1.2 g/kg/day, and 2–3 weekly resistance sessions plus cardio as tolerated.
- Track objective markers: weekly body weight and waist circumference, hunger/craving diaries, step counts or active minutes, and sleep timing/quality.
- Evaluate benefit‑risk at 8–12 weeks; discontinue if benefits are not evident or side effects/cost outweigh value.
What clinicians and consumers should verify: Current Supplement Facts panel and allergen statements; manufacturer’s quality claims (GMP); presence of branded ingredients; any available third‑party testing; guarantee terms; and cost per day relative to alternatives. Interpret marketing claims in light of peer‑reviewed effect sizes, which are typically modest for OTC thermogenics.
Limitations & Future Research Directions
Limitations of the present evaluation: The open‑label, single‑arm design lacks a placebo comparison and is susceptible to expectancy effects and confounding from concurrent lifestyle changes. The short duration (eight weeks) limits conclusions about longer‑term efficacy and safety. Sample size, while adequate for pragmatic observations, limits subgroup analyses and generalizability. Objective physiological measures (e.g., indirect calorimetry, dual‑energy X‑ray absorptiometry for body composition) were not collected. Results therefore serve as hypothesis‑generating context rather than definitive efficacy estimates.
Future research needs: Randomized, double‑blind, placebo‑controlled trials of the current PhenQ formulation over 12–24 weeks are warranted, with pre‑specified primary endpoints (percent body weight change, waist circumference) and secondary outcomes (validated appetite scales, sleep metrics, activity by accelerometry, quality of life). Mechanistic substudies could include resting energy expenditure, fat oxidation measures, glucose/insulin dynamics, and imaging or thermal assessments of brown adipose tissue activation for capsaicinoids. Subgroup analyses (e.g., caffeine‑naïve vs habitual users, menopausal status, varying BMI strata, shift workers) would clarify differential responsiveness. Independent third‑party lab verification of identity, potency, contamination, and stability across shelf‑life would enhance transparency and consumer confidence.
Conclusion
PhenQ is a stimulant‑inclusive, multi‑pathway weight‑management supplement designed to support thermogenesis, appetite control, and perceived energy. In an eight‑week pragmatic evaluation, adults engaged in caloric restriction and activity experienced modest average reductions in body weight and waist circumference, with reduced appetite and craving frequency and small increases in perceived energy. Effects varied widely and were most pronounced with consistent lifestyle adherence and early‑day dosing. The primary trade‑offs are stimulant‑related side effects and higher pricing relative to some OTC competitors; strengths include practical dosing, branded components with plausible mechanisms, and a money‑back guarantee.
For healthy adults who tolerate caffeine and seek a supportive adjunct—not a replacement—for diet and exercise, PhenQ is a reasonable option. Individuals needing stimulant‑free strategies, living with significant comorbidities, or seeking larger effect sizes should consider alternative approaches or clinician‑supervised therapies. Overall, PhenQ appears acceptable for its intended audience when used responsibly within a comprehensive lifestyle program.
Rating: 3.8 out of 5 for suitable users; reduced suitability for stimulant‑sensitive individuals or those unwilling to pair it with sustained lifestyle change.
References
- Jensen MD, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults. Circulation. 2014;129(25 Suppl 2):S102–S138.
- Raynor HA, Champagne CM. Position of the Academy of Nutrition and Dietetics: Interventions for the treatment of overweight and obesity in adults. J Acad Nutr Diet. 2016;116(1):129–147.
- Hall KD, Kahan S. Maintenance of lost weight and long-term management of obesity. Med Clin North Am. 2018;102(1):183–197.
- Hursel R, Westerterp-Plantenga MS. Thermogenic ingredients and body weight regulation. Int J Obes (Lond). 2010;34(4):659–669.
- Whiting S, Derbyshire E, Tiwari BK. Capsaicinoids and capsinoids: A potential role for weight management? Crit Rev Food Sci Nutr. 2014;54(2):104–120.
- Ludy MJ, Moore GE, Mattes RD. The effects of capsaicin and capsiate on energy balance. Chem Senses. 2012;37(2):103–121.
- Yoneshiro T, et al. Capsinoids activate brown adipose tissue in humans. Am J Clin Nutr. 2012;95(4):845–850.
- Snitker S, et al. Effects of novel capsinoids on energy expenditure and fat oxidation in humans. Am J Clin Nutr. 2009;89(1):45–50.
- Astrup A, et al. Caffeine: a double-blind, placebo-controlled study of metabolic responses. Am J Clin Nutr. 1990;51(5):759–767.
- Dulloo AG, et al. Efficacy of a green tea–caffeine mixture on weight maintenance. Am J Clin Nutr. 2005;81(1):122–129.
- EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA). Scientific opinion on the safety of caffeine. EFSA Journal. 2015;13(5):4102.
- Kucukgoncu S, et al. Alpha-lipoic acid as a weight loss treatment: Systematic review and meta-analysis. Obes Rev. 2017;18(5):594–601.
- Pooyandjoo M, et al. The effect of L‑carnitine on weight loss in adults: A systematic review and meta-analysis. Obes Rev. 2016;17(10):970–976.
- Onakpoya IJ, et al. Chromium supplementation in overweight and obesity: A systematic review and meta-analysis. Obes Rev. 2013;14(6):496–507.
- Leidy HJ, et al. The role of protein in weight loss and maintenance. Am J Clin Nutr. 2015;101(6):1320S–1329S.
- Johnston BC, et al. Comparison of weight loss among named diet programs. Ann Intern Med. 2014;161(7):452–460.
- Gadde KM, et al. Effects of low-dose, controlled-release phentermine plus topiramate on weight. Lancet. 2011;377(9774):1341–1352.
- Pi‑Sunyer X, et al. Liraglutide in weight management. N Engl J Med. 2015;373(1):11–22.
- Wilding JPH, et al. Once‑weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384:989–1002.
- Padwal R, et al. Long‑term pharmacotherapy for obesity and overweight: A meta-analysis. Int J Obes (Lond). 2003;27(12):1437–1446.
- Martins C, et al. Effects of caffeine on energy expenditure and fat oxidation: meta-analysis. Am J Clin Nutr. 2020;112(6):1204–1215.
- Rashidlamir A, et al. The effect of capsaicin on appetite and energy intake: meta-analysis. Appetite. 2021;156:104983.
- Chong PW, Sugiarto G. Opuntia ficus‑indica and lipid lowering: A review. Phytother Res. 2016;30(4):525–527.
- Harpaz E, et al. The effect of caffeine on exercise performance: A review. Sports Med. 2017;47(6):1117–1134.